June 17, 2025
Marie Austin, Director of Marketing, ATCA

At Alzheimer’s Treatment Centers of America (ATCA) in Port St. Lucie, we combine cutting-edge diagnostics, breakthrough medications like TB006, and over 50 advanced therapies to tackle Alzheimer’s and cognitive decline head-on. Here’s a deeper look at how each element of our personalized approach works—and why science shows it can make a real difference.

Schedule Your FREE Brain Health Screening

Call: #250, say keyword “Memory Loss”

CNS Vital Signs is an FDA‑cleared, computerized neurocognitive assessment tool that provides precise, objective data on memory, attention, processing speed, and executive function—all in just 7 minutes, no needles or imaging required.

Why Early Detection Matters

Early detection is paramount. Cognitive decline often begins decades before symptoms emerge, and tools like CNS Vital Signs can reveal subtle changes years ahead of time. Over 20 million tests administered globally demonstrate its reliability and utility in clinical settings.

Schedule Your Screening Today

By establishing a detailed cognitive baseline, our clinicians can identify issues early, track progress over time, and customize treatment with evidence-based clarity.

Claim Your FREE Brain Health Screening NOW

Patented AI Protocol Targets 200+ Root Causes

ATCA’s groundbreaking patented AI system dives deep—analyzing up to 200 known biological, environmental, and genetic factors that contribute to Alzheimer’s and cognitive decline. Most patients accumulate around 30 underlying root causes over 20 years. By spotlighting the unique triggers in each individual, we can craft highly specific treatment regimens designed to halt or reverse cognitive impairment.

TB006: A Game-Changing Anti‑Tau Therapy

How It Works

TB006 is a humanized monoclonal antibody that targets Galectin-3, a protein that promotes inflammation and aggregation of amyloid-beta and tau—key culprits in Alzheimer’s pathology. By binding to Galectin-3, TB006 prevents these proteins from clumping and may even help break down existing plaques.

Promising Clinical Results

In early clinical trials, nearly 50% of participants showed cognitive stabilization or improvement over 3 months. Ongoing studies continue to explore its impact on disease progression and patient quality of life.

TB006 is available at ATCA through FDA-approved expanded access programs, offering hope to those seeking cutting-edge solutions.

Therapeutic Plasma Exchange (TPE): Blood Renewal for Brain Health

What TPE Does

TPE removes plasma laden with toxic proteins like amyloid-beta and replaces it with healthy albumin solutions. Think of it as a blood “reset” to reduce neuroinflammation.

Evidence of Impact

The AMBAR trial reported up to a 60% reduction in cognitive decline, with improvements in language fluency, processing speed, and daily function. Animal studies also confirm a reduction in amyloid plaques after TPE.

At ATCA, TPE is carefully integrated into each patient’s treatment timeline to amplify the benefits of other therapies.

50+ Complementary Therapies Working in Synergy

Beyond TB006 and TPE, ATCA’s holistic toolkit includes:

• IV Nutrient Therapy – Restores essential vitamins, antioxidants, and co-factors for brain health.
• Energy & Light Therapies – Stimulate mitochondrial activity and rejuvenate neuronal function.
• Hormone Optimization – Rebalances hormones essential for cognition and mood regulation.
• Oxygen Therapy – Enhances brain tissue oxygenation and metabolic function.
• Neuroplasticity Exercises & Cognitive Support – Builds mental resilience and functional independence.

These therapies are thoughtfully combined based on each individual’s diagnostic profile, with the goal of maximizing synergy and impact.

75% of Patients See No Further Decline

With ATCA’s Patented AI Protocol, 75% of patients experienced no further decline in their Mild Cognitive Impairment (MCI) in an observational 2.5 year study.

Take Action Now: It Starts with a Free Screening

Alzheimer’s is insidious—it starts quietly, but the time to act is now. A FREE, 7-minute CNS Vital Signs assessment offers:

• Early detection of subtle cognitive changes
• A personalized diagnostic roadmap
• Entry to precision therapies—including TB006 clinical trials
• Ongoing tracking of cognitive progress

You can schedule your free assessment by calling #250 and saying “Memory Loss” or visiting ATCA.ai/screening.

Why ATCA’s Precision Model Matters

• Data-Driven CNS Vital Signs + AI diagnostics = targeted interventions based on actual biology.
• Innovative Treatments TB006 and Therapeutic Plasma Exchange are among the most promising therapies in today’s Alzheimer’s pipeline.
• Holistic & Personalized Every treatment plan is tailored—including hormones, nutrients, oxygen, energy therapy—to address each patient’s unique needs.
• Evidence of Effectiveness 75% of patients saw no further decline in their mild cognitive impairment (MCI) in a 2.5 year observational study using our patented AI protocol.
• Community & Caregiver Support ATCA provides educational resources, emotional support, and guided care for families and caregivers.

Final Thoughts: Hope in Action

Alzheimer’s is not a sentence—it’s a call to action. With early detection and a precision-driven protocol, real progress is possible. ATCA in Port St. Lucie stands ready to bring new hope to seniors and families—with science, compassion, and transformative care.

📞 Dial #250 and say “Memory Loss” or
🖱️ Click to schedule your FREE brain health screening now

Because cognitive health isn’t just a wish—it’s within reach.

Schedule Your Brain Health Consultation Now

“Alzheimer’s Treatment Centers of America brought my wife back.”

We Work With Insurance Carriers on Your Behalf
Schedule Your FREE Screening

Call: 772‑298‑4477

© Alzheimer Treatment Centers of America, all rights reserved.

*Each patient is unique. No representation is being made that new patients would have similar results. Each patient responds to the protocol based on their current condition.